Physician profile
Jewel Barboza
NPI 1063868099
$13,353.76
in general payments reported to CMS, 2019-2025
28 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,700 · 2022: $2,983 · 2023: $2,671 · 2024: $4,124 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,589 · Consulting Fee: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,588.93 |
| Consulting Fee | $2,081.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $2,542.19 | 2021-2024 | Aplenzin, Wellbutrin |
| Abbvie INC. | $2,093.52 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,548.32 | 2021-2025 | Caplyta |
| Corium, LLC | $1,020.16 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $898.93 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $841.10 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $679.75 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $582.93 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $550.97 | 2021-2025 | Lybalvi, Aristada |
| Avanir Pharmaceuticals, INC. | $413.15 | 2021-2022 | |
| Lundbeck LLC | $351.62 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $315.77 | 2021-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $259.19 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $215.87 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $204.83 | 2022-2025 | Austedo Xr, Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $141.90 | 2022-2024 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $127.01 | 2024-2025 | Rejoyn |
| Currax Pharmaceuticals LLC | $90.34 | 2021-2022 | |
| Almatica Pharma LLC | $84.77 | 2022-2023 | Loreev Xr, Gralise |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.36 | 2025 | |
| Vanda Pharmaceuticals INC. | $64.05 | 2021-2022 | |
| Neos Therapeutics, Lp | $55.43 | 2023-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $46.13 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $37.37 | 2024-2025 | Relexxii |
| Adlon Therapeutics L.P. | $34.27 | 2021 | |
| Jazz Pharmaceuticals INC. | $32.03 | 2021 | |
| Indivior INC. | $19.49 | 2021 | |
| Collegium Pharmaceutical, INC. | $19.31 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jewel Barboza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.